Expressions of B7-H1 and Bcl-2 in epithelial ovarian cancer and their clinical significance

Abstract

Abstract:ObjectiveTo investigate the expressions of B7-H1 and Bcl-2 proteins in epithelial ovarian cancer, and to explore the association of the expressions of B7-H1 and Bcl-2 with clinicopathological features. MethodsThe expressions of B7-H1 and Bcl-2 proteins were detected by immunohistochemistry in 80 cases of epithelial ovarian cancer tissues and 20 normal ovary tissues. The association of the expressions of B7H1 and Bcl2 with the clinicopathological features was analyzed. ResultsThe positive expression rates of B7H1 and Bcl2 in epithelial ovarian cancer tissues were 77.5% (62/80) and 58.8% (47/80), both higher than 15.0% (3/20) and 10.0% (2/20) in normal ovary tissues with significant difference （χ2=27.473, P＜0.05; χ2=15.216, P＜0.05）. Both of Bcl2 and B7H1 expressions in epithelial ovarian cancer tissues were negatively correlated with the differentiation degree of epithelial ovarian cancer (χ2=9.367， P＜0.01； χ2=11.702， P＜0.01). The Bcl-2 expression in epithelial ovarian cancer tissues was positively correlated with the FIGO stage (χ2=7.766, P＜0.01). The expression of B7-H1 was positively correlated with the expression of Bcl2 in epithelial ovarian cancer (r=0.400, P＜0.01). ConclusionThe expressions of B7-H1 and Bcl-2 are upregulated in epithelial ovarian cancer and they correlate to each other positively. The expressions of B7-H1 and Bcl-2 are correlated with the invasion and metastasis of epithelial ovarian cancer. The detection of B7-H1 combined with Bcl-2 may have an important clinical significance in the diagnosis and treatment for patients with epithelial ovarian cancer.

Key words:Ovarian neoplasms,Gene,B7-H1,Bcl-2,Immunohistochemistry

Hao Zhiqiang, Li Xiaofeng, Yu Dedong, Bai Xuefeng. Expressions of B7-H1 and Bcl-2 in epithelial ovarian cancer and their clinical significance[J]. Journal of International Oncology, 2015, 42(1): 18-21.

References

［1］ Dong H, Zhu G, Tamada K, et al. B7H1, a third member of the B7 family, costimulates Tcell proliferation and interleukin10 secretion［J］. Nat Med, 1999, 5(12): 1365-1369. ［2］ Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7H1 (PDL1) on paraffinembedded slides of pancreatic adenocarcinoma tissue［J］. J Vis Exp, 2013, 71: 4059. ［3］ Hua D, Sun J, Mao Y, et al. B7H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma［J］. World J Gastroenterol, 2012, 18(9): 971978. ［4］ Muller CY. Doctor, should I get this new ovarian cancer testOVA1?［J］. Obstet Gynecol, 2010, 116 (2 Pt 1): 246-247. ［5］ Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer［J］. Proc Natl Acad Sci USA, 2007, 104(9): 33603365. ［6］ Azuma T, Yao S, Zhu G, et al. B7H1 is a ubiquitous antiapoptotic receptor on cancer cells［J］. Blood, 2008, 111(7): 3635-3643. ［7］ Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD1 and are functionally impaired［J］. Blood, 2009, 114(8): 1537-1544. ［8］ Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7H1 is associated with poor prognosis in renal cell carcinoma patients with longterm followup［J］. Cancer Res, 2006, 66(7): 3381-3385. ［9］ Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death1 ligand1 and programmed death1 ligand2 expression in human esophageal cancer［J］. Clin Cancer Res, 2005, 11(8): 2947-2953. ［10］ Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy［J］. Oncogene, 2007, 26(9): 1324-1337. ［11］ Li P, Zhang ST, Yu ZL, et al. Effects of cyclooxygenase2 nonselective and selective inhibitors on proliferation inhibition and apoptosis induction of esophageal squamous carcinoma cells［J］. Dis Esophagus, 2009, 22(1): 2131. ［12］ Anderson NS, Turner L, Livingston S, et al. Bcl2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation［J］. J Ovarian Res, 2009, 2: 16. ［13］ Kang MH, Reynolds CP. Bcl2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy［J］. Clin Cancer Res, 2009, 15(4): 1126-1132. ［14］ Zhang Z, Wu G, Gao J, et al. Inclusion complex of a Bcl2 inhibitor with cyclodextrin: characterization, cellular accumulation, and in vivo antitumor activity［J］. Mol Pharm, 2010, 7(4): 1348-1354. ［15］ Avraam K, Pavlakis K, Papadimitriou C, et al. The prognostic and predictive value of ERCC1, p53, bcl2 and bax in epithelial ovarian cancer［J］. Eur J Gynaecol Oncol, 2011, 32(5): 516-520.

[1]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[2]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[3]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.
[4]	Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui.Role of ABRACL in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 544-547.
[5]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[6]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488.
[7]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[8]	Wu Jiali, Zhang Jiahui, Zhang Ping, Xiao Xinyue, Li Rui, Zhang Hongyu.Mechanism of Bcl-2 BH4 selective inhibitor BDA-366 on NK/T cell lymphoma cells[J]. Journal of International Oncology, 2023, 50(7): 413-418.
[9]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[10]	Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin.Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer[J]. Journal of International Oncology, 2023, 50(5): 263-267.
[11]	Liu Bohan, Huang Junxing.Research progress of solute carriers related genes in malignant tumors[J]. Journal of International Oncology, 2023, 50(5): 280-284.
[12]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[13]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang.Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion[J]. Journal of International Oncology, 2023, 50(2): 71-75.
[14]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[15]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.